Mauna Kea Technologies and Cook Medical Enter Into a Global Multi-year Commercialization Partnership for Endomicroscopy in Urology

Dec 10, 2015, 13:43 ET from Mauna Kea Technologies

PARIS, December 10, 2015 /PRNewswire/ --

 

  • Cook Medical will commercialize a private-labeled version of Cellvizio for urologic applications 
  • Planned launch in North America, Western Europe and China in the first half of 2016 

Mauna Kea Technologies (Euronext: MKEA, FR0010609263, PEA-PME eligible), inventor of Cellvizio®, the multi-disciplinary confocal laser endomicroscopy (CLE) platform, announced today it has entered into a global commercialization partnership with Cook Medical for urology applications of its unique Cellvizio platform.

Cook Medical, a privately-held company with more than 11,000 employees and headquarters in Bloomington, Indiana, is among the world's best-known and most respected names in medical devices and supplies and a world leader in urology applications.

"We're extremely pleased to partner with a global market leader such as Cook Medical to address the urology market with our unique confocal laser endomicroscopy technology," said Sacha Loiseau, founder and CEO of Mauna Kea Technologies. "This first global commercial partnership is a major milestone of our new strategy to commercialize our innovative technology through private labeling or integration of our Cellvizio platform with established leaders in a range of indications."

Under the terms of the agreement, Cook Medical will launch a private-labeled version of the Cellvizio platform for urologic applications in the first half of 2016. With their international expertise in sales, marketing and medical education and their comprehensive complementary product portfolio in urology, Cook has the potential to rapidly maximize the commercial opportunities for Cellvizio.

Urologic applications of confocal laser endomicroscopy with Cellvizio may include detection and surveillance for cancer recurrence among the 500,000+ people living with bladder cancer in the United-States, and the characterization of upper urinary tract urothelial cancer (UTUC).

"While we focus resources on the execution of our commercialization partnership with Cook Medical, we are continuing to work to develop additional indications for Cellvizio that will position us to explore many new partnership opportunities in the coming year and beyond," concluded Mr. Loiseau.

About Cook Medical 

Founded in 1963, Cook Medical pioneered many of the medical devices now commonly used to perform minimally invasive medical procedures throughout the body. Today, the company integrates medical devices, drugs and biologic grafts to enhance patient safety and improve clinical outcomes. Since its inception, Cook has operated as a family-held private corporation with now more than 11,000 employees. For more information, visit www.cookmedical.com

About Mauna Kea Technologies 

Mauna Kea Technologies is a global medical device company focused on protecting patients' lives while enabling physicians and surgeons to make better decisions thanks to direct visualization at the cellular level. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit http://www.maunakeatech.com


Mauna Kea Technologies                                        
Sebastien Cadet                   
Global Marketing Director and     
OEM leader                        
Tel: +33(0)1-70-08-09-70         
communications@maunakeatech.com  

France and Europe           
NewCap - Investor Relations 
Florent Alba/Pierre Laurent 
Tel: +33(0)1-44-71-94-94   
maunakea@newcap.fr         

United States 
Berry & Company Public Relations 
Bill Berry 
Tel: +1-212-253-8881 
bberry@berrypr.com


SOURCE Mauna Kea Technologies